Madison Muller

If only Eli Lilly & Co had listened to Richard DiMarchi, it could have been first to the $80 billion weight-loss drug market. Three decades ago, DiMarchi was working as a scientist at the Indianapolis-based drugmaker, studying a gut hormone called glucagon-like peptide-1. In a small trial, he showed that an infusion of the hormone caused weight loss in humans. The finding was so promising that he and a collaborator filed for patent protection on their discovery.

Biography:  https://www.bloomberg.com/news/features/2024-01-26/zepbound-how-eli-lilly-s-lucky-break-fueled-a-600b-weight-loss-empire

61%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

75%

Examples:

  • The author uses sensationalism by stating that sotatercept will be among Merck's hits as sales from successful older drugs begin fading later this decade. This statement implies that sotatercept will be a huge success and generate significant revenue for Merck when there is no evidence to support this claim.

Conflicts of Interest

50%

Examples:

  • The author uses selective reporting by only mentioning the cost of Winrevair without providing any context or comparison with other treatments available in the market.
  • The author uses sensationalism by stating that sotatercept will be among Merck's hits as sales from successful older drugs begin fading later this decade. This statement implies that sotatercept will be a huge success and generate significant revenue for Merck when there is no evidence to support this claim.

Contradictions

85%

Examples:

  • The drug will cost $14,000 per vial and will be taken every three weeks.
  • Winrevair is the first FDA-approved activin signaling inhibitor therapy for PAH.

Deceptions

50%

Examples:

  • The author uses selective reporting by only mentioning the cost of Winrevair without providing any context or comparison with other treatments available in the market.
  • The author uses sensationalism by stating that sotatercept will be among Merck's hits as sales from successful older drugs begin fading later this decade. This statement implies that sotatercept will be a huge success and generate significant revenue for Merck when there is no evidence to support this claim.

Recent Articles

Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

Broke On: Friday, 03 May 2024 Amgen, a California-based biotech company, announced its focus on MariTide, an injectable obesity drug in Phase 2 trials with promising interim results. Patients lost an average of 14.5% body weight in 12 weeks according to phase one data. Amgen plans late-stage studies and expansion of manufacturing capacity for this differentiated obesity treatment.
New Drug Approved for Treatment of Rare and Serious Condition, Pulmonary Arterial Hypertension (PAH)

New Drug Approved for Treatment of Rare and Serious Condition, Pulmonary Arterial Hypertension (PAH)

Broke On: Wednesday, 27 March 2024 A new drug called WINREVAIR has been approved by the FDA for treating pulmonary arterial hypertension (PAH), a rare and fatal condition that affects mostly women. The drug works by regulating a growth factor that is overproduced in PAH patients, potentially altering the disease's biology. WINREVAIR improved exercise capacity and other outcomes in clinical trials compared to background therapy alone.

FDA Approves Eli Lilly's Zepbound for Weight Loss

Broke On: Wednesday, 08 November 2023 FDA has approved Eli Lilly's drug tirzepatide, marketed as Zepbound, for weight loss. Zepbound works by activating two naturally produced hormones in the body, slowing the emptying of the stomach and suppressing appetite. The cost for a month's supply of Zepbound is $1,059.87, cheaper than a similar weight-loss drug, Wegovy, priced at $1,349 for a month's supply.